Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients

Neurotrophic tyrosine receptor kinase gene fusions (<i>NTRK</i>) are oncogenic drivers present at a low frequency in most tumour types (<5%), and at a higher frequency (>80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive wi...

Full description

Bibliographic Details
Main Authors: Sébastien Perreault, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan D. Wasserman, Stephen Yip
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Current Oncology
Subjects:
<i>NTRK</i>
larotrectinib
entrectinib
targeted therapy
molecular testing
oncogenic drivers
Online Access:https://www.mdpi.com/1718-7729/28/1/38

Internet

https://www.mdpi.com/1718-7729/28/1/38

Similar Items